The agency is currently reviewing the study findings ...
In A Nutshell • A brain stimulation device cleared by the FDA in 2019 failed to beat placebo in a rigorous 150-participant ...
With one in seven American children and teens now diagnosed with attention-deficit/hyperactivity disorder (ADHD) and psychostimulant medication (amphetamines such as ...
NeuroSigma Inc., a bioelectronics company based in Westwood, received federal clearance to market the first medical device to treat childhood ADHD, or attention deficit hyperactivity disorder. The U.S ...
Brain stimulation devices have been marketed as a drug-free alternative to ADHD medication. But a major new UK trial found no ...
The device gained FDA approval in 2019 based on data from a placebo-controlled clinical trial that included 62 children with moderate to severe ADHD. NeuroSigma’s Monarch external Trigeminal Nerve ...